US5225538A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lymphocyte homing receptor/immunoglobulin fusion proteins
Assignee: Genentech Inc
•
Filing: 1991-12-16
•
Granted: 1993-07-06
•
Expires: 2011-12-16
Abstract
Abstract Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.
Inventors
- 👤 Daniel J. Capon
- 👤 Laurence A. Lasky
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:19
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/30; C07K2319/32; C07K2319/70; C07K2319/705
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
17 words
A polypeptide fusion comprising a ligand binding partner protein which comprises a LHR and an immunoglobulin chain.
Claim 2
Dependent Claim
17 words
A polypeptide fusion comprising a ligand binding partner protein which comprises a LHR and an immunoglobulin chain.
Claim 3
Dependent Claim
13 words
The polypeptide of claim 1 wherein the ligand binding partner is a LHR.
Claim 4
Dependent Claim
25 words
The polypeptide of claim 1, wherein the ligand binding partner protein and the immunoglobulin chain are fused through C- or N-terminal amino or carboxyl groups.
Claim 5
Dependent Claim
29 words
The polypeptide of claim 3, wherein a portion of the constant domain of the immunoglobulin chain is linked at its N-terminus to the C-terminus of said ligand binding partner.
Claim 6
Dependent Claim
30 words
The polypeptide of claim 3, wherein the Fc portion of the constant domain of the immunoglobulin chain is linked at its N-terminus to the C-terminus of said ligand binding partner.
Claim 7
Dependent Claim
22 words
The polypeptide of claim 3, wherein the immunoglobulin chain sequence is obtained from IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgD or IgM.
Claim 8
Dependent Claim
10 words
The polypeptide of claim 3, joined to a detectable marker.
Claim 9
Dependent Claim
11 words
The polypeptide of claim 3, wherein said immunoglobulin sequence is human.
Claim 10
Dependent Claim
12 words
The polypeptide of claim 3, wherein said ligand binding partner is human.
Claim 11
Dependent Claim
18 words
The polypeptide of claim 3, wherein the immunoglobulin chain is the constant domain of an IgG heavy chain.
Claim 12
Dependent Claim
23 words
The polypeptide of claim 3, wherein the ligand binding partner is an LHR which binds to the high endothelial venules of lymphoid tissue.
Claim 13
Dependent Claim
8 words
The polypeptide of claim 3, unassociated with glycosylation.
Claim 14
Dependent Claim
10 words
The polypeptide of claim 3, in a physiologically acceptable carrier.
Claim 15
Dependent Claim
13 words
The polypeptide of claim 13, wherein the carrier is a sterile, isotonic solution.
Claim 16
Dependent Claim
12 words
The polypeptide of claim 13, wherein the carrier is a sustained-release formulation.
Claim 17
Dependent Claim
11 words
The polypeptide of claim 13, wherein the carrier is a liposome.
Claim 18
Dependent Claim
20 words
The polypeptide of claim 3, wherein said ligand binding partner protein in the fusion is incapable of cell membrane anchorage.
Claim 19
Dependent Claim
17 words
The polypeptide of claim 3, wherein said immunoglobulin is from a different species than said binding partner.
Claim 20
Dependent Claim
34 words
The polypeptide fusion of claim 3, wherein the ligand binding partner is a first ligand binding partner, said fusion further comprising an additional fusion of a second ligand binding partner and an immunoglobulin chain.
Claim 21
Dependent Claim
20 words
The polypeptide fusion of claim 19 wherein the second ligand binding partner is different from the first ligand binding partner.
Claim 22
Dependent Claim
24 words
The polypeptide fusion of claim 19 wherein the first ligand binding partner fusion and second ligand binding partner fusion are crosslinked by disulfide bonds.
Claim 23
Dependent Claim
22 words
The polypeptide fusion of claim 19 wherein the first ligand binding partner fusion and second ligand binding partner fusion are noncovalently aggregated.
Claim 24
Dependent Claim
22 words
The polypeptide fusion of claim 20 wherein the first ligand binding partner is LHR and the second ligand binding partner is CD4.
Claim 25
Dependent Claim
49 words
The polypeptide of claim 23, wherein said ligand binding partner is a LHR having a LHR carbohydrate binding domain, a LHR epidermal growth factor domain, and a LHR complement binding domain, and wherein said LHR carbohydrate binding domain has been deleted or replaced by a heterologous carbohydrate binding domain.
Claim 26
Dependent Claim
53 words
The polypeptide of claim 23, wherein said ligand binding partner is a LHR having a LHR carbohydrate binding domain, a LHR epidermal growth factor domain, and a LHR complement binding domain, and wherein said LHR epidermal growth factor binding domain has been deleted or replaced by a heterologous epidermal growth factor binding domain.
Claim 27
Dependent Claim
49 words
The polypeptide of claim 23, wherein said ligand binding partner is a LHR having a LHR carbohydrate binding domain, a LHR epidermal growth factor domain, and a LHR complement binding domain, and wherein said LHR complement binding domain has been deleted or replaced by a heterologous complement binding domain.
Claim 28
Dependent Claim
50 words
The polypeptide of claim 23, wherein said ligand binding partner is a LHR having a LHR carbohydrate binding domain, a LHR epidermal growth factor domain, a LHR complement binding domain, a LHR cytoplasmic domain and a LHR transmembrane domain, and wherein said LHR cytoplasmic and transmembrane domains have been inactivated.
Claim 29
Dependent Claim
46 words
A polypeptide fusion comprising a first ligand binding partner protein which comprises a LHR and an immunoglobulin chain, said fusion further comprising an additional fusion of a second ligand binding partner and a stable plasma protein, wherein said first and second ligand binding partners are different.
Claim 30
Dependent Claim
46 words
A polypeptide fusion comprising a first ligand binding partner protein which comprises a LHR and an immunoglobulin chain, said fusion further comprising an additional fusion of a second ligand binding partner and a stable plasma protein, wherein said first and second ligand binding partners are different.
Claim 31
Dependent Claim
22 words
The polypeptide fusion of claim 28, wherein each of said immunoglobulin chain and said stable plasma protein are immunoglobulin constant domain sequences.
References Cited (Backward Citations)
EP0125023A1
Cited
EP0173494A2
Cited
EP0207402A2
Cited
EP0271227A2
Cited
EP0288809A1
Cited
EP0294703A2
Cited
EP0308381A1
Cited
EP0308936A2
Cited
EP0314317A1
Cited
EP0322094A1
Cited
WO1989004872A1
Cited
EP0325262A2
Cited
EP0346316A2
Cited
WO1990002338A1
Cited
WO1990005144A1
Cited
EP0386906A1
Cited
EP0391088A2
Cited
EP0394827A1
Cited
EP0399666A1
Cited
WO1990014103A1
Cited
WO1991000360A1
Cited
EP0413622A1
Cited
EP0414178A2
Cited
WO1991004329A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-07-05 | 1997-01-04 | 1997-07-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-07-05 | 2001-01-04 | 2001-07-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-07-05 | 2005-01-04 | 2005-07-06 | $7700.00 | Window Closed / Lapsed |